This study is testing a drug called sonelokimab for adults with active psoriatic arthritis (a type of arthritis linked to psoriasis) who haven't responded well to previous anti-TNFα (tumor necrosis factor alpha) treatments. Researchers want to see if sonelokimab is effective and safe compared to a placebo (an inactive substance) and another drug called risankizumab. You might be able to join if you are at least 18 years old, have had psoriatic arthritis for at least six months, and have active disease with a certain number of tender and swollen joints. The main goal is to see how many participants achieve at least a 50% improvement in their symptoms after 16 weeks.

Study design

This is a Phase 3, randomized, double-blind study involving about 600 participants. It compares sonelokimab to a placebo and risankizumab.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at Week 16, but the total follow-up duration is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.